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Abstract
Background: Pneumococcal disease is a transmitted infectious illness that results in serious
complications and death every year in the United States. Given their increased susceptibility to
the potential complications of this disease, patients aged 65 and older are considered to be highrisk, but vaccination compliance for this population remain well below state and national goals.
Purpose: The purpose of this project was to increase pneumococcal vaccination rates among
adults aged 65 and older in a primary care clinic by increasing patient education.
Methods: An educational intervention was implemented within a large primary care practice
located in Central Massachusetts. Educational materials were distributed within the clinic,
including posters, vaccine information sheets, and flyers. Cumulative vaccination rates for
pneumococcal pneumonia among the target population were analyzed pre and post intervention
to evaluate project impact. Mixed methods were used for analyzing project results.
Results: Results demonstrated a nearly 10% increase in cumulative vaccination rates after project
implementation. There also proved a statistically significant relationship between patient
education and rates of vaccination exists (p < .0001).
Conclusion: The project’s findings demonstrate that increasing patient education in the primary
care setting can improve rates of vaccination against pneumococcal pneumonia in vulnerable
patient populations.
Keywords: pneumococcal, pneumonia, patient education, standing order programs,
vaccination, immunization, barriers, older adults.
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Introduction and Background
Introduction
Vaccines are arguably one of the most powerful medicines available to patients to prevent
illness and reduce infectious disease morbidity and mortality. The Centers for Disease Control
and Prevention (CDC) (2014) recommends routine vaccinations from birth through adulthood to
provide a lifetime of protection against vaccine preventable diseases. Notable increase in
average life expectancy during the last century is associated with decreased rates of infectious
disease mortality attributable to vaccinations. As one of the most cost-effective clinical
preventive services, investment into vaccines yields a high return (U.S. Department of Health
and Human Services [HHS], 2014). Currently, the Advisory Committee on Immunization
Practices (ACIP) recommends twelve different immunizations for adults ages 19 and older,
including two specific to preventing pneumonia: Pneumococcal polysaccharide vaccine (PPSV23) and Pneumococcal conjugate vaccine (PCV-13) (CDC, 2015).
Pneumococcal disease is an easily transmitted, significantly infectious illness that results
in massive expense, complications and death every year in the U.S. (American Lung Association
[ALA], 2010). High-risk patients aged 65 and older are more susceptible to potential
complications associated with pneumonia as it often exacerbates underlying illnesses. Older
individuals are more likely to experience respiratory failure, sepsis, lung abscesses or even death.
Pneumococcal disease claims the lives of one in every four to five people over the age of 65 that
contracts it and in 2013, was responsible for 53,282 deaths in the U.S.; together with influenza it
is currently the fifth leading cause of death in the older adult (NFID, 2015). Communityacquired pneumonia is responsible for 350,000-620,000 hospitalizations for older adults annually
and survival rates among this population are lower than younger individuals; furthermore, those
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who may survive the initial illness sustain a higher-than-normal morbidity rate in forthcoming
years. With the baby boomer generation aging, it is anticipated that disease incidence will rise
proportionately. The CDC (2011) has estimated that by the year 2030 the number of U.S. adults
65 years and older will have doubled to approximately 71 million; simultaneously, life
expectancy will continue to increase, introducing a greater opportunity for these diseases to
wreak their havoc on society.
Background
Pneumococcal disease places a financial burden on the U.S.; in 2004 an estimated four
million episodes of illness resulted in direct medical costs of $3.5 billion, half of which ($1.8
billion) were related to care of patients aged 65 and older (Huang et al., 2011). It is projected
that pneumococcal pneumonia hospitalizations will increase by 96% between 2004 and 2040.
Without intervention the increasing demand for healthcare services will double in coming
decades, and the total cost of pneumococcal pneumonia will increase by $2.5 billion annually
(Wroe et al., 2012). However, approximately 70 million adults considered high-risk remain
unvaccinated (CDC, 2013). Healthy People 2020 maintains a target goal of a 90% vaccination
rate for pneumonia in adults 65 years and older, but with current data exhibiting a suboptimal
total of 59.7%, disparities in vaccination rates clearly exist (CDC, 2013; HHS, 2014).
A multitude of factors contribute to whether an individual will seek medical treatment,
including vaccination. Health service or treatment must be perceived by the individual to be
important, beneficial to their wellbeing, easily available and affordable (ALA, 2010). From a
global perspective, lack of resources and infrastructure play a large role in barring efforts to
promote preventive care. In certain developing countries, citizens struggle to pay for basic
medical procedures and consider anything greater than basic a luxury (Pfizer, 2012). Within the
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U.S. issues pertaining to cost appear to be less concerning for patients than personal awareness or
beliefs (ALA, 2010). Reported barriers have also included a lack of awareness of the disease
and/or vaccine, competing priorities, time restraints, incomplete or unobtainable immunization
histories and delivery challenges within the health care system (Rehm et al., 2012). With
coverage levels not attaining nationwide goal, infectious disease still remains prevalent in society
and there is a consequential need to develop, understand and promote interventions in primary
care that will increase immunization rates. This quality improvement DNP project investigated
the feasibility of increased patient education having an impact on pneumococcal pneumonia
vaccination rates among patients 65 and older in a primary care setting.
Problem Statement
Risk of serious health complications from pneumococcal pneumonia among U.S. patients’
ages 65 and older has been made evident by consistently high morbidity and mortality rates from
vaccine preventable pneumococcal pneumonia related to suboptimal vaccination coverage
resulting from a multitude of perceived personal and logistical barriers among patients and
providers alike.
Literature Review
A search of the literature was conducted to identify and critique existing methods to
improve pneumococcal vaccination rates among patients aged 65 years and older. The review
further sought to identify patient and provider perceived barriers to immunization.
Standing Orders Program
Standing orders programs (SOP) as recommended by the ACIP allow non-provider
personnel to assess the vaccination status of patients and administer vaccines without an
individual physician order. An outline of the ACIP’s report on their recommendations is
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available to review in Appendix A. The Immunization Action Coalition (2014) has developed a
multitude of SOPs allowing eligible staff (i.e. nurses and pharmacists) within approved states the
autonomy to identify and subsequently vaccinate individuals that meet specified criteria;
standing orders already exist for both pneumococcal vaccines (PPSV23 and PCV13) with an
ultimate goal of reducing overall morbidity and mortality from pneumococcal disease. A copy
of the existing orders protocol is provided in Appendix B. The review specifically identifies
current evidence within the literature pertaining to SOPs, including barriers to implementation
and successes achieved when said barriers are eliminated.
Methods
The initial search included the following databases: PubMed and Google Scholar. Prior
to undergoing the search, texts published by experts in systematic reviews were utilized for
reference on database selection and search term development. Medical Subject Headings
(MeSH) terms included a varying combination of the following: pneumococcal, pneumonia,
vaccination, immunization, rates, improving, interventions, and older adults. Two additional
terms were later included to further expand the search: standing order programs and SOP. After
an initial review was undergone, the DNP student chose to isolate and explore literature
pertaining specifically to the interventional use of Standing Order Programs (SOP) and the
benefits increased patient education has on increasing vaccination rates.
Inclusion criteria consisted of full-text articles published in the English language within
the past 5 years (2010-2015). Retrospectively, a larger time span may have been beneficial as
there were limited publications available. Articles were filtered to focus on the community
setting in order to maximize primary care relevance. Those non-specific to adults 65 years of
age and older were used sparingly but not omitted, as some provided high-quality analysis of
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SOP implementation. Studies focusing on interventions other than standing order programs were
not evaluated, unless the intervention was used in combination with a standing order. Initial
search yielded 482 articles, which were further delineated into 15 sources, each scrutinized
according to specific criteria of reliability, validity and applicability to future research and
practice scenarios. Nine articles were chosen for final synthesis and major patterns and gaps
across the literature pertaining to this possible intervention were identified.
Results and Synthesis of the Evidence
The Johns Hopkins Nursing Evidence-based Practice Rating Scale (JHNEBP) was
utilized to assess methodological quality of the literature. For the quantitative studies,
internal/external validity and reliability were taken into account, while credibility, transferability
and generalizability were considered in reviewing the qualitative.
Benefits to Vaccination. Multiple studies have validated the claim that vaccination
against pneumonia will decrease risk for potential complications (CDC, 2015). In a study of
approximately 85,000 adults 65 years and older in the Netherlands, researchers found PCV-13
was effective at preventing invasive pneumococcal disease and 45% effective at preventing
pneumococcal pneumonia (Mangen et al., 2015). Bonten et al. (2015) conducted a similar study
among 84,496 adults within the United States in which one group was vaccinated and the other
was not. Just as in the study by Mangen et al., researchers identified a positive correlation
between pneumococcal vaccination and rates of illness: Community-acquired pneumonia was
diagnosed in 49 vaccinated individuals versus 90 in the unvaccinated placebo group (vaccine
efficacy, 45.6%; 95.2% CI, 21.8 to 62.5); invasive pneumococcal disease was recognized in 7
individuals of the PCV13 group and 28 in the placebo (75.0%, 95% CI, 41.4 to 90.8). Both
studies demonstrate that pneumococcal vaccination is effective in preventing disease.
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A single dose of PPSV-23 is recommended routinely for adults 65 and older as an
effective means of preventing invasive pneumococcal disease (ACIP, 2010). However, data on
the vaccine’s effectiveness against community-acquired pneumonia is inconsistent and various
studies have been unable to provide adequate evidence proving PPSV-23 effective against noninvasive pneumococcal pneumonia (NPP) among older adults in the community (Huss et al.,
2009; Moberly, Holden, Tatham & Andrews, 2008). The addition of PCV-13 into the older adult
population is predicted to improve coverage against this type of pneumonia and studies are being
undergone for further exploration (Smith et al., 2012). Currently, the ACIP recommends
immunocompetent older adults receive both vaccines as a way to broaden their coverage against
varying strains of pneumonia. Patients 65 and older that have previously been vaccinated with
PPSV-23 should receive a single dose of PCV-13 at least one year after having received the
PPSV23. For those adults 65 and older that have not received either pneumococcal vaccination,
a single dose of PCV-13 should be given first, followed by a dose of PPSV-23 six to twelve
months later.
Efficacy of Standing Order Protocol Use. Current literature suggests use of SOPs as an
effective means of raising rates of vaccinations (Appel, 2011). The United States Preventive
Services Task Force (USPSTF) recommends the use of SOPs as a highly graded preventive tool
and members of the American Academy of Family Physicians (AAFP) further support belief in
SOP efficacy. Evidence demonstrates a direct correlation exists between implementation of an
SOP and increased vaccination rates (Albert et al., 2012; Bardenheier et al., 2010; Nowalk et al.,
2014; Zimmerman et al., 2011). Nowalk et al. (2014) conducted an observational study among
providers from four diverse primary care practices (Level II, Grade B). Utilizing group
interviews and surveys as reliable tools to measure outcomes, researchers implemented use of an
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SOP toolkit and found PPSV rates of high-risk adult patients increased from 25% to 40% in just
one year. Results of the study indicated minimal effect on the older adult population, revealing
inconsistency in the study’s findings. However, influenza vaccination rates exhibited significant
improvement in three out of four sites overall (22% vs.33%, p < .001), justifying the researchers’
claims of SOPs positively impacting rates of vaccination.
Similarly, Bardenheier, Shefer, Lu, Remsburg and Marstellar (2010) also yielded positive
results from their cross-sectional study of a randomized sample of 11,939 nursing home residents
65 years and older (Level I, Grade A). Aiming to assess the impact of SOPs vs. alternative
programs on influenza vaccination rates, the researcher identified a positive relationship between
use of standing orders and greater vaccination coverage (66.7% versus 62.0%, respectively, P <
.01). In congruence with the previous study’s conclusions, Middleton et al. (2008) also proved
that utilization of an SOP is a cost-effective method for increasing rates of pneumococcal
vaccination among hospitalized elderly patients. Newly admitted patients to a 1,094 bed tertiarycare hospital were screened for PPSV eligibility and then offered the vaccine resulting in overall
vaccination rates increased by 30.5%. More research will be beneficial in analyzing the impact
of SOPs on alternative outpatient locations.
In continued support of the previous findings, Smith and Metzger (2011) conducted an
experimental pre-test/post-test study among 300 randomly selected adult patients of two separate
Internal Medicine units. The sample was isolated into two groups of 150 patients with the
purpose to determine if a multifaceted vaccine protocol inclusive of standing orders would
increase rates of screening and vaccination among eligible patients. The overall screening rate
was similar between both pre and post-implementation groups (96% vs. 93%). However, the
rate of vaccination was significantly different (19.1% to 74.2%, respectively). Within their
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analysis, researchers highlighted findings from a prospective, randomized controlled study
conducted by Dexter et al. (2004) in which patients designated to an electronic standing order
group had higher rates of vaccination against pneumonia opposed to a group using electronic
reminders as an intervention (51% vs. 31%, respectively, p <0.001). Methods of measurements
for both studies were reliable and data successfully demonstrate noteworthy findings consistent
with previous studies included in this review: Standing order programs are an effective method
of increasing vaccination rates.
Correlates of SOP Use. Despite proven benefit to increasing vaccination rates,
consistent underutilization of SOPs signifies barriers exist to implementation. In a nationally
represented sample of 880 physicians, Albert, Nowalk, Yonas, Zimmerman and Ahmed (2012)
indicated only 23% of providers reported consistent use of SOPs (Level I, Grade A). The
researchers aimed to identify factors either promoting or impeding the use of SOPs. Reliability
was strengthened through use of a survey that is national in scope and maintains a high provider
response rate, while the questionnaire was rooted in concepts from various theoretical models.
Investigators determined that consistent SOP use for influenza and pneumonia vaccination was
significantly impacted by provider awareness of ACIP recommendations and/or Medicare
regulations as those reporting consistent use of SOPs were typically more aware of said
regulations and recommendations. The same team conducted an additional study among 1,640
providers and findings were similar, identifying the two variables mostly highly associated with
a provider’s likelihood of using SOPs as awareness of recommendations to use them and
agreement with their efficacy (Zimmerman, Albert, Nowalk, Yonas & Ahmed, 2011). Both of
these studies concluded providers who used them found they are beneficial; however, they also
bring to light a need for greater awareness and methods to increase use of SOPs in primary care.
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Comparative findings were elicited by researchers Zimmerman et al. (2011) who
conducted a quasi-experimental study among a stratified random sample of 1,640 providers
within the U.S. (Level II, Grade B). Consistent SOP use was reported slightly higher than the
previous study at 42.4%. The percentage of providers aware of ACIP/Medicare
recommendations and regulations was 35.8% in the group not currently using SOPs, compared to
70.9% in the group that was aware. These findings further justify that awareness is critical to
ensure successful implementation of an SOP and increase rates of vaccination; to be considered
however, the method of data collection via survey is limited to self-report. Regardless, methods
that will increase use of SOPs are implicated for future research.
Barriers to Immunization. A multitude of barriers related to vaccine delivery exist
within society as perceived by both patients and providers. Much of the current literature aims to
identify these barriers and address potential methods of alleviating them in attempts to raise
vaccination rates. A common theme across the literature is missed vaccine opportunities and the
contribution it has to low vaccination rates. In one retrospective study of 1,072 female girls
between the ages of 18-24, it was found that 33.7% of the girls who did not receive their second
vaccine in the series had at least one identifiable missed opportunity (Richards, Peters &
Sheeder, 2014). Similarly, Nowalk et al. (2005) conducted a cross-sectional analysis of 4,000
patients in multiple primary care practices over a span of four years, yielding results with high
sensitivity and generalizability. The researchers identified an average of 10.7 +/- 7.3 missed
opportunities for vaccination of adults 65 and older against pneumococcal pneumonia during the
period of one year.
Specific to provider and patient reported barriers, a survey conducted amongst 238
OB/GYN U.S. medical residents reported barriers to immunization, which included uncertainty
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over vaccine recommendations, safety and efficacy and a lack of time to properly inform patients
of the risk and benefits to vaccination (Fay, Hoppe, Schulkin & Eckert, 2014). It should be noted
that these results are limited to providers of a medical specialty and may not be applicable to all
providers. Rehm et al. (2012) summarized similar findings elicited from a multidisciplinary task
force meeting on ways to increase pneumococcal vaccination rates among older adults. Barriers
to vaccination included lack of awareness of the vaccine or disease, health care system delivery
challenges and competing priorities that restricted the time available for vaccine discussion.
Researchers Suryadevara et al. (2013) identified similarly expressed barriers in their study and
attempted to eliminate them and improve rates of vaccination. They partnered with the Salvation
Army to educate families on childhood immunizations and by doing so, rates of vaccination
increased from 28% to 45%. Although further study specific to barriers again pneumococcal
pneumonia vaccination in the older adult population is warranted, each of these articles
successfully highlighted the significance of missed opportunities on vaccination rates.
Summary of Evidence
As research has demonstrated, disparities in pneumonia vaccination rates exist among the
older adult population. Despite the known efficacy and availability of vaccines, millions remain
unvaccinated (ALA, 2010). Barriers to full immunization do exist, but sufficient evidence
proves they are surmountable. Development and implementation of this program will address
ways in which health care providers can begin rectifying the issue, starting with the simple task
of increasing their awareness to existing recommendations and patient awareness to vaccine
benefits; successful intervention will aid in minimizing this disparity by expanding provider’s
abilities to offer patient services aligned with nationally established goals for prevention and
control against vaccine preventable disease. Vaccinations help to eliminate health disparities
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while simultaneously advancing health equity among the population. Utilizing detailed
screening and not relying solely on the providers will help reduce the number of missed
opportunities within this vulnerable population, and implementation of SOPs will positively
affect vaccination rates.
Theoretical Framework
Lewin’s Change Theory
In order to successfully motivate a collaborative team and advance toward achieving an
optimal goal, one must be familiar with the concept of change and its theoretical underpinnings
(Zaccagnini & White, 2014). Developed by ‘the father of social psychology’, Kurt Lewin, the
Change Theory of Nursing recognizes change as a constantly evolving factor of life, driven by a
dynamic balance of forces working in opposing directions (Lewin, 1951; Lewin, 1975;
Zaccagnini & White, 2014). The social scientist believed driving forces facilitated change by
pushing individuals in the desired direction, while restraining forces pushed individuals in
opposite directions, consequently preventing it (Kritsonis, 2005). Lewin’s theory is based on the
belief that change process must go through three stages: unfreezing, moving, and refreezing
(Lewin, 1951; Lewin, 1975; Zaccagnini & White, 2014).
The first stage is unfreezing. This step in the process identifies needs of an individual or
group, while simultaneously preparing those involved to move forward from the existing
situation, or status quo, to an improved level of practice. The unfreezing phase helps to identify
a potential method that will allow people to let go of counterproductive processes and is
necessary to overcome strains of individual resistance and group conformity. Kritsonis (2005)
recognizes three ways unfreezing can be achieved: a) increase the driving forces which will aid
in redirecting behavior away from the existing situation or status quo; b) eliminate restraining
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forces responsible for hindering movement from the existing equilibrium; c) formulating a
combination of the two previous methods.
Once those involved are motivated to change, the second stage in the process can take
place: moving. The movement phase zeroes in on what exactly needs to be changed. It
involves addition of driving forces as a means of motivating and empowering individuals/the
group to adopt a new and improved prospective; additionally, this phase attempts to minimize
opposing forces that pose potential barriers to achieving the desired change (Lewin, 1951;
Lewin, 1975; Zaccagnini & White, 2014). The focus here is to move the target system to a
new level of equilibrium with the assistance of competent leader (Kritsonis, 2005).
The final stage, freezing, involves making the change permanent and cannot successfully
occur until the change has been implemented (Lewin, 1951; Lewin, 1975; Zaccagnini & White,
2014). The purpose of this stage is to stabilize the new equilibrium by maintaining a balance
between driving and restraining forces, and if this is done poorly, or not at all, the risk for
reverting back to old behaviors is high (Kritsonis, 2005). To ensure completion of this stage,
leaders must consistently reinforce the new level of practice and promote continued use by
members.
Theory Application in Implementation
A comprehensive breakdown of the theory’s major concepts and their applicability to the
capstone project are reviewed below. Driving forces were identified as supporting evidencebased research, improved patient outcomes and decreased hospitalizations, decreased healthcare
costs, and improved patient/staff safety. Restraining forces included lack of perceived benefit,
fear of adverse effects and lack of perceived severity of illness and provider’s lack of awareness
to how little patients knew of this disease and available vaccines.
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Unfreezing phase. Achieving this step required an increase in driving forces and
decrease in restraining forces. This was accomplished by providing more educational materials
on pneumococcal pneumonia and allowing patients the opportunity to ask questions and voice
concerns during office visits. Engaging patients instilled a sense of empowerment, helping them
to overcome their resistance to change and gain a greater understanding of how important the
need for change was (Sutherland, 2013). Additionally, this time was used to discuss existing
statistics with staff and providers, making them more aware of the need for increased education.
Moving phase. The moving phase included implementation of the intervention. During
this time, posters were placed in the waiting room; flyers were placed in each exam room and
handed out to patients at both check-in and check-out, in addition to provision of VIS forms.
Patients were encouraged to read the available material and ask questions during their visit in
order to increase their knowledge of pneumococcal pneumonia and recognize the benefits of
vaccination.
Freezing phase. Bozak (2003) identifies the need for the theory’s final stage to include
stability and evaluation, which the DNP student achieved through the provision of ongoing
support of all stakeholders during implementation of the intervention. Adequate follow-up with
patients and providers/staff offered a chance for feedback and ensured the new equilibrium was
maintained.
Project Design and Methods
The project design looked at benchmark change in cumulative vaccination rates through
use of an educational intervention aimed at both patients and the clinic. Pre and post
intervention data was analyzed to assess the impact of the project. Project data was analyzed
using mixed qualitative and quantitative methods. The project intervention ran from November
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2015 through February 2016. Data regarding immunization rates for pneumococcal disease in
the target population adults age 65 years and older was gathered and analyzed pre and postimplementation, quantifying the number of eligible patients that received vaccination at each
time interval and comparing results; this was completed with the assistance of the Information
Technology department.
Planning Model: CHIP
The Community Health Improvement Process (CHIP) provides a systematic approach for
how communities can identify and manage prevalent health issues in specified populations
(IOM, 1997; Layde et al., 2012). The model is separated into two cycles to further delineate key
elements (Appendix C). The first cycle, identification and prioritization, aided the DNP student
in conducting the needs assessment and determining which health issue needed to be addressed;
it is comprised of 3 core elements:
•

Form a community health coalition

•

Prepare and analyze community health profiles

•

Identify critical health issues

Completion of the first cycle indicated a need for improving pneumonia vaccination rates.
Subsequently, the student was able to initiate the second cycle of analysis and implementation,
addressing seven additional elements:
•

Analyze health issue

•

Inventory resources

•

Develop health improvement strategy

•

Identify accountability

•

Develop indicator set
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Implement strategy

•

Monitor process and outcomes
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The CHIP model provided a framework for guiding the implementation of the capstone project
and the assessment of outcomes for the future.
Needs Assessment
Community of Interest. The chosen site for implementation was a group medical
practice established in Central Massachusetts with 14 sites providing primary care and satellite
sites providing specialty services. Project implementation occurred at only one of the primary
care locations. The selected practice had a panel of approximately 12,000 patients, ranging from
young adults to elderly, and nine providers: six MDs and four APRNs. The providers saw on
average anywhere between 80 and 130 patients a day for a combination of well and sick visits.
Demographics within the practice were consistent with the surrounding town of Westborough,
representing a dominantly middle to upper class Caucasian and Indian population. The target
population for project implementation included adults 65 years of age and older eligible for
pneumococcal vaccination within the primary care setting; patients were excluded if they were
new to the practice within the previous three months.
Utilizing the feedback of multiple providers within the department through verbal
discussion, it was determined that an intervention focusing on increasing vaccination rates was
desired. Most providers felt that the numbers of patients receiving the currently recommended
vaccinations were lacking and wanted to see these numbers increase; although, there were a
select few that did not feel their numbers were far off from national baselines. Many patients felt
improved efforts needed to be made by healthcare offices to remind patients when they are due
for vaccines. Interviewed individuals felt that if they forgot to ask about a vaccine they may
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have seen on TV (i.e. the new CDC recommendations for PCV13) it may not have necessarily
been recommended during the visit. Statistical data was gathered to accurately demonstrate
vaccination rates within this department. Additionally, further investigation was undergone to
highlight missed opportunities for vaccinating patients and identifying existing barriers (i.e.
during a regular office visit vs. physical). This information assisted the DNP student in
identifying gaps or deficits comparatively speaking.
Organizational Analysis
Identifying the Key Stakeholder. The key stakeholder for this project was a Master’s
prepared FNP who works closely with her supervising physician, a family medicine doctor with
nearly 40 years of experience in primary care. On average she sees 15-20 patients a day,
primarily 18 years and older, for both well and sick visits. Although she does not have a panel of
her own, she is well known to patients throughout the office and they often seek her care
directly.
Resources, Facilitators and Barriers. Resources necessary to complete the capstone
project included: time, location, materials and email communication. Time was managed
throughout the entire process to account for development, implementation and analysis of the
quality improvement project. A specific location was necessary to implement the project and
approval to utilize this site was necessary to obtain. Email was necessary to stay in constant
contact with project stakeholders, particularly the IT department. Materials included the supplies
necessary for poster construction, paper and printer for flyer production and Vaccine Information
Sheets, all of which helped facilitate information to patients. Poster supplies were obtained on
the DNP student’s budget, while the rest of the material was made available by the project site.
Each of these interventional tools was beneficial in facilitating communication about
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pneumococcal pneumonia between patients and providers.
Vaccine Information Sheets (VIS) developed by the CDC were already being provided to
patients in adherence to national regulations. The CDC ensures these informational sheets are
up-to-date; the PCV-13 VIS was most recently updated in November of 2015 and PPSV-23 in
April of 2015. Each of these is available in multiple patient languages and written in layman’s
terms for patients to comprehend. They explain to patients, parents or legal representatives of
the individual being vaccinated, what the risks and benefits are to vaccination and address many
of the commonly asks questions associated with the vaccination.
Existing standard workflow processes within the office facilitated the project. Trained
nurses were available to administer vaccines or answer patient’s questions. A designated nursing
room allowed a space for patients to receive vaccines without having to wait and delay rooming
of other patients, which was a perceived barrier expressed amongst office staff. The office
maintained stock of all necessary materials to facilitate vaccine administration, including PCV-13
and PPSV-23 vaccines, needles, gauze and band aids. Additionally, a crash cart with all items
necessary for an emergency was readily available and appropriate staff was knowledgeable of its
contents. VIS forms were already present in all exam rooms and the nursing room; open
communication between DNP student and staff ensured that these were consistently offered to
patients.
Potential barriers to project implementation were identified as provider/staff reluctance,
lack of knowledge of vaccination coverage and an assumption of patient’s lack of perceived need
and severity of illness. Some providers were reluctant to rescind responsibilities of identifying
eligible patients, while some expressed concern over it being the nurse’s sole responsibility to
decide whether or not vaccination was appropriate. Staff and providers identified their lack of
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knowledge of vaccination coverage was a barrier to facilitating adequate monitoring of vulnerable
patients. Data gathered for pre-implementation analysis was provided to staff and providers to
accurately depict vaccination rates within the department and demonstrate a need for
improvement.
It was determined that due to Internal Medicine and Pediatric departments combining for
their annual flu clinic implementation during the clinic was too large of an undertaking. The
additional requirements on staff mentally, physically and financially were deemed too
overwhelming. It was determined among student and key stakeholder that the SOP would be
best implemented as a part of the standard daily workflow. By October, significant barriers to
implementation became evident. The company was undergoing a major layoff, management was
reconstructing itself and employees at all levels were under great amounts of stress. By
November, the clinical nurse lead, and another key stakeholder for the project, resigned. This
was detrimental to project implementation as this nurse leader had been in support of the project
and was helping facilitate nursing’s adaptation. The DNP student met with the key stakeholder
and practice manager in December to discuss plausible solutions.
Project Implementation
Ethics and Human Subjects Protection
The chosen methods of design and evaluation were submitted to the UMass Amherst
Institutional Review Board and determined to be exempt given the proposed activities were not
considered research under the human subject regulations (Appendix D). To avoid violation of
HIPPA laws, the student at no time had access to any patient’s protected health information and
their confidentiality was maintained. To alleviate potential for representation of human subject
research, the project was limited to the use of existing and/or prospectively collected de-
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identified patient data; IT gathered and supplied all necessary data for analyzing.
Project Timeline
A flow chart was developed to identify the program’s major processes and is available for
review in Appendix E. Constant reference to the original timeline and flowchart were made
throughout the implementation process, allowing the student opportunities to acknowledge
obstructing factors and ensure programmatic needs of the project were effectively being
addressed.
Pre-intervention. The DNP student had previously met with both the project’s key
stakeholder and office practice manager in late August 2015 and was granted permission to
implement the project at their location. Discussion at that time included the following key points
that pertained to the proposed project’s design and evaluation methods:
•

Outcome goal: Determine if the intervention demonstrates a relationship between the
health intervention program and the health outcome of the population (increased
pneumonia vaccination rates among adults age 65 and older).

•

Project design: Quasi-experimental, pre and post-intervention.

•

Methods of evaluation:
i. Quantitative data analysis/interpretation: 1) Pre and post intervention
evaluation of the statistics pertaining to vaccination rates among patients 65
and older within the practice.
ii. Qualitative: Provision and review of patient and provider responses to an
open-ended survey regarding the proposed intervention.
Communication with the IT department via email and phone occurred and data on

current pneumococcal immunization rates for patients within the target audience was made

IMPROVING PNEUMONIA VACCINATION RATES

23

available to the student. All data were given de-identified patient codes so as not to compromise
patient confidentiality.
By the end of October 2015 the project’s tactile materials were constructed to promote
project awareness. Flyers on pneumococcal pneumonia and vaccine promotion in patients 65
and older were designed, printed and offered to patients during both check-in and check-out;
they were also hung in patient exam rooms (Appendix F). A poster board presentation with
similar information was created and placed in the office waiting room for patients to view. The
office previously had vaccine information sheets available for both PCV-13 and PPSV-23 in the
nursing treatment room. The DNP student collaborated with staff and was able to have materials
placed in all patient exam rooms by the end of October 2015. By mid-October a PowerPoint
presentation on pneumococcal pneumonia was developed and a copy of the pneumococcal
pneumonia vaccine eligibility screening tool developed by the Immunization Action Coalition
(2015) was printed and copied for providers and staff to review at the first educational session
(Appendix G). In addition, a survey was constructed to gain feedback from attendees at the
educational session (Appendix H). The survey included questions specific to the content of the
DNP student’s presentation and three open-ended questions pertaining to the proposed capstone
as a whole.
During the early phases of implementation the company underwent a large layoff and
scheduling conflicts occurred frequently due to structural changes and a need to address pressing
issues within the company. As a result, the DNP student was not able to present the project as
anticipated. Rather, multiple conversations were had between student and individual staff that
would be affected by the project, including nurses, providers, medical assistants and secretaries.
Despite ample support from key stakeholders and an overall desire within the office to improve
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pneumococcal vaccination rates, mostly everyone were significantly less receptive to the idea
that this would require a change in the workflow process.
At the onset of the project the DNP student had engaged in multiple conversations with
the clinical nurse supervisor who was in strong support of carrying out a standing orders
program; however, by the end of October she had resigned and remaining staff nurses adamantly
refused to adopt the proposed project. Concerns were raised regarding recent layoffs and budget
cuts placing too significant of a strain on their already understaffed team and they did not want to
assume the responsibilities that came with a standing orders program. Validation of their
concerns was provided and it was acknowledged that a change in project focus was necessary.
In the best interest of all participants involved in the project, it was decided that the DNP student
would remove the existing intervention of a standing orders program and place emphasis on the
educational component of the project. By increasing the presence of informational material on
pneumococcal pneumonia and available vaccinations, the hope was that immunization rates
would raise.
During Intervention. During this interval the DNP student maintained supervision and
offered support to patients and staff as necessary. Periodic inspection of the project site was
conducted by the student to ensure that posters were visible to patients, VIS forms were
consistently being offered and flyers were being offered to patients appropriately. Service
utilization outputs were tracked, such as the number of materials developed for the
implementation of the project and overall work flow, and a running log of project activities was
maintained.
Post-intervention. Interpersonal information system outputs were requested and
included all reports generated by IT. The final report was generated and supplied to the student
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via email. Inputs and outputs to the service utilization plan were reviewed and quantified during
this phase as necessary. This included tracking of program coverage through collection of deidentified patient data via IT to determine if the target audience had been reached successfully.
Results were analyzed to determine the effectiveness and future applicability of the quality
improvement project. During the months of March and April 2016 the program was evaluated
and discussions regarding program intervention delivery were had between the student and
project facilitators. Dissemination of project findings is projected to occur at the College of
Nursing Scholarship Day, held on May 5, 2016 at the University of Massachusetts Amherst.
Project Evaluation
Data Analysis and Results
The project identified three major goals, each of which had associated objectives and
specific measurable outcomes utilized to achieve the overarching goals of the project (Appendix
I). Analysis and interpretation of the data collected from IT was undergone to assess whether
project goals were met and complete a program evaluation.
Goal I: Identify a multidisciplinary team within primary care to design and
implement a program that meets both state and federal regulatory requirements and
national vaccination goals. Each of the objectives and measurable outcomes for this goal were
specific to implementation of a standing orders program. Given an SOP was not successfully
implemented, objectives could not be met, and this goal by default was considered unattained.
However, an alternative educational program was successfully implemented.
Goal II: Ensure all eligible adults age 65 and older in primary care are effectively
motivated and informed of current pneumococcal vaccination recommendations and
provided an opportunity for vaccination. Again, failure to implement an SOP within the

IMPROVING PNEUMONIA VACCINATION RATES

26

office was a significant deterrent to satisfying all measurable outcomes of this goal. However,
despite the fact that original measurable outcomes were not met, the individual objectives were;
therefore, this goal was arguably achieved.
Objective i: Establish baseline data for vaccination rates of patients aged 65 and older
in the practice. Baseline data was successfully obtained from IT by October 2015. From a total
clinic panel of 10,601 patients, it was established that 2,049 met the inclusion criteria for the
project. Of the eligible patients, 1,636 were shown to have previously received either one or
both of the available pneumococcal pneumonia vaccines. This objective was successfully met.
Objective ii: Identify and eliminate missed vaccine opportunities. Although this
objective was not met with regards to the specified outcome measures, the DNP student did
engage in individual in-depth interviews with providers and patients during the pre-intervention
phase of the project to discuss barriers to vaccination and gain feedback on why they believed
opportunities were missed. Critical analysis of provider and patient responses was conducted.
The two most common responses elicited from providers included frequent need to prioritize
other concerns during office visits and the subsequent lack of adequate time to discuss the
vaccine with their patients; however, providers expressed feeling methods to alleviate these
barriers were scarce. Similarly, patients felt dependent on their providers to raise the discussion
of vaccines. Lack of disease and vaccine awareness was also a major barrier identified by
patients.
Objective iii: Increase patient awareness of pneumococcal disease and vaccine
availability. Nearly 100% of adult patients 65 and older had flyers readily available to them at
check-in. Informational flyers and an educational poster board were constructed by September
2015 and made available for patient viewing by October 2015. Additionally, patient and provider
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responses to open-ended discussion yielded positive feedback. The patients approached all
expressed an appreciation for the increased presence of educational material and providers noted
patients inquiring about the vaccine more frequently than previously. The data was obtained
sporadically and patient responses were not tracked; therefore, critical analysis of these results
could not be completed.
Goal III. Reduce overall morbidity and mortality caused by pneumococcal disease
among adults age 65 and older in primary care. In order to adequately assess outcomes and
evaluate whether the goal was met at project completion, the DNP student requested four
specific data sets from the IT department to evaluate project impact; they included (a) the total
number of patient’s on the clinic’s panel; (b) the total number of those patients 65 years and
older not new to the practice within the last three months; (c) the total number of those patients
65 years and older that have received either or both pneumococcal vaccines (PCV-13 and PPSV23); (d) the total number of those patients 65 years and older that have not received either
vaccine. IT conducted two separate reports to reflect data before and after intervention. Table 1
provides a comparative summary of results for each individual dataset before and after
intervention and reveals the nearly 10% increase of cumulative vaccination rates among the
target population after project implementation.
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Table 1
Data Comparing Pneumococcal Vaccination Rates in Adults 65 and Older Within Primary Care
Before and After an Educational Intervention

Cumulative % a
Dataset

Pre-Intervention

Post-Intervention

Total # of patients in clinic

10,601

10,816

Total # of patients ≥ 65 y/o b

2,049

1,994

Vaccinated c

1,636

1,788

413

208

Unvaccinated c

Pre

Post

79.84%

89.67%

Note. De-identified patient data collected from Reliant Medical Group, Active Patient Panel reports: November
2015 and February 2016.
a

Cumulative percentages were calculated specifically utilizing pre and post-intervention samples separately.

b

Only patients that met inclusion criteria (adults age 65 and older, not new to the practice within the previous 3
months and eligible to receive either vaccine without contraindication).
c

Total # calculated from patient sample that met inclusion criteria; these totals do not reflect the vaccination rates
for the entire clinic’s panel; includes both PCV-13 and PPSV-23. Individuals were counted only once as
“vaccinated” regardless if they had received both or either vaccination multiple times.

Objective i: Expand immunization services. The measurable outcome for this objective
aimed to have at least 75% of patient’s age 65 and older complete screening and receive a
pneumococcal vaccine if determined eligible under the standing orders. This outcome was
realistically unattainable as an SOP was not implemented.
Objective ii: Increase the annual immunization rates of adults age 65 and older who
are vaccinated against pneumonia in primary care. Primary data analysis was conducted using
a chi-square test to determine whether increased patient education was directly related to
increased vaccination rates. Nominal values included 1) before vs. after project intervention, and
2) how many patients were and were not vaccinated against pneumonia. Utilizing the statistics
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from Table 1, results indicated there was a statistically significant relationship between patient
education and rates of vaccination χ2 (1) =73.74, p < .001.
Descriptive analysis of the February 2016 active patient report yielded clinically
significant results. Approximately 1,788 (89.67%) patients age 65 and older in the primary care
clinic had received either, or both, the PCV-13 and PPSV-23 vaccines, compared with 1,636
(79.84%) in November 2015 (p=<.0001). There was an overall increase of 9.83% in cumulative
vaccination rates from project baseline. Furthermore, the number of those unvaccinated was
nearly cut in half after project implementation was complete (see Figure 1).
Prior to the intervention, vaccination rates for the clinic among the target population were
10.16% below Healthy People 2020 benchmark goal of 90%; the intervention minimized that
gap to only 0.33% (see Figure 2). The objective’s measurable outcomes called for a 20%
improvement of cumulative vaccination rates and a match to the Healthy People 2020 goal of
90%; therefore, the objective could only be observed as partially met.
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Figure 1. Patient pneumococcal vaccination status pre and post an educational
intervention.
The bar graph compares pneumococcal vaccination rates among patients 65 years and
older in a primary care setting. Individuals were considered vaccinated if they had received
either, or both, PCV-13 and PPSV-23 and unvaccinated if they had received neither. The
decrease in number of unvaccinated patients is consistent with the increase of total patients
vaccinated. Relative to the sample sizes before intervention (n=2,049) and after intervention
(n=1,994), there was an overall cumulative vaccination rate increase of 9.83% among the total
number of eligible patients vaccinated before and after project implementation (79.84% to
89.67%, respectively).
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Figure 2. Pre and post intervention cumulative pneumococcal vaccination rates compared
to the target goal of Healthy People 2020.
This bar graph is a quantitative comparison of cumulative pneumococcal vaccination
rates among the sample population before and after the educational intervention was
implemented. Patients included in the sample were adults 65 and older that were not new to the
practice within the previous 3 months. Results clearly demonstrate the 9.8% increase from
baseline. The results are displayed in relation to their achievement of Healthy People’s 2020
benchmark goal of 90%, which is indicated by the red target line.
Discussion
Despite the fact that not all project objectives were met in terms of instituting standard
orders the project did demonstrate the benefits of increased patient education on rates of
vaccination. Although the initial goal of implementing an SOP was not achieved, the fact that an
alternative educational intervention was planned and implemented in accordance with both
national and state guidelines cannot be discredited. The U.S. Department of Health and Human
Services (HHS) has established numerous initiatives and programs designed with the same
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overarching goal in mind: strengthening adult vaccination. This project aligned specifically with
objectives and indicators of Healthy People 2020 and the Agency for Healthcare Research and
Quality. The project also built on existing initiatives at the state level as specified by the
Massachusetts Department of Public Health (MDPH) (Executive Office of Health and Human
Services, 2015). As is the case with many of state projects, development of this capstone project
followed recommendations of the CDC, including implementation of measurable increases and
reduction of disparities in adult immunization rates (CDC, 2015). Results of the project support
previous studies that determined cumulative vaccination rates increased with the use of an
educational intervention (Kemp, 2008; Yu, 2015). These successes implicate both immediate
and long-term achievement of a major project goal: Reduce overall morbidity and mortality
caused by pneumococcal disease in the target population.
The Healthy People 2020 target goal of 90% vaccination in this population lay right
outside of reach and suggests that sustained efforts to improve cumulative vaccination rates
through patient education are necessary. However, it is of interest to note that 41 patients were
excluded from the data analysis post-intervention as they were new to the practice within the
previous three months. Of these, 31 were vaccinated with either, or both, PCV-13 and PPSV-23.
If data were to be collected on pneumococcal vaccination rates without consideration to this
exclusion criteria, the true total number of vaccinated patients 65 and older within the clinic
would be 1,819 (1,788 + 31); therefore raising the clinic’s cumulative vaccination rate to 91.22%
and exceeding the Healthy People 2020 benchmark goal of 90%.
The project goal to expand immunization services could understandably not be met,
strictly because achievement of the measurable outcome required implementation of an SOP.
However, by preventing missed vaccination opportunities in the future, eliminating barriers to
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immunization and increasing overall patient awareness on pneumococcal pneumonia, the
project’s outcomes certainly aid in the expansion and improvement of vaccination services
within the primary care clinic. The project identified patient and provider barriers that were
largely consistent with those identified in previous qualitative studies (Albert et al., 2012; Appel,
2011; Burns & Zimmerman, 2006; Hurley et al., 2014; Rehm, 2012; Richards et al., 2014).
Furthermore, the project’s findings also support the use of patient education as a quality tool for
removing certain barriers (Suryadevara et al., 2013). This reinforces the notion that improved
efforts to identify barriers to immunization are necessary to improve pneumococcal vaccination
rates among adults 65 and older in primary care (Rehm, 2012). Further research on methods to
eliminate common barriers to vaccination is necessary.
Similar to previous research findings, providers felt that the increased education resulted
in more patients mentioning the vaccine during visits and patients reported feeling better informed
of the disease and vaccines (Smith & Metzger, 2011; Suryadevara et al., 2013; Yu, 2015).
Additionally, critical analysis of the responses clearly supported prior researcher’s claims that
increased presence of educational material in primary care clinics subsequently increased the
amount of patients inquiring about the vaccines (Nowalk et al., 2014). It should be noted that
open-ended discussion was conducted among random patients and providers and may have
limited generalizability; furthermore, future studies of a similar nature would benefit from
tracking the number and responses of individuals interviewed to analyze data more accurately and
avoid potential threats to project validity. Regardless, the project’s findings underscore the need
to increase patient education on pneumococcal pneumonia and available vaccinations.
Results of this DNP project also add to existing literature suggesting that Lewin’s Theory
of Change can be utilized as framework to motivate acceptance of change among both patients
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and providers. Lewin’s theory argues that in order for change to be successful, three phases must
occur: unfreezing, moving and freezing (Lewin, 1951; Lewin, 1975; Zaccagnini & White, 2014).
The provider’s acknowledgment of driving and restraining forces to immunization throughout the
unfreezing and moving phases reminded them of the integral role they play in ensuring patients
are well informed of vaccine recommendations. Of equal importance, the framework also guided
patients in recognizing and accepting responsibility of their role in maintaining their health; thus
improving the level of practice among both entities. The clinic has proven able to adopt Lewin’s
theory and could benefit from continued efforts in identifying and eliminating gaps in healthcare
quality by utilizing the framework.
Study Limitations. This study was subjected to several limitations. Most significantly,
the implementation of a standing orders program was unsuccessful due to changes in the
workplace. The initial implementation of an SOP seemed feasible for both student and project
key stakeholders but structural barriers within the company were too significant to overcome.
Additionally, the loss of support from the nurse lead resulted in significant resistance from the
nurses, whose participation was crucial to project success. Future studies of a similar nature
would benefit from greater involvement of multidisciplinary stakeholders to act as liaisons
between student and staff.
Limitations also existed within the study’s methods and designs. First, the pre-post
intervention design was most feasible given timing and logistical constraints; however, without
follow-up it lacks the ability to evaluate long-term effectiveness of the intervention. Second,
participants were recruited from a convenience sample, lacking randomization or inclusion of a
control group. Inability to control variables limits the ability to make casual inferences and
leaves question surrounding whether there may have been alternative explanations for the

IMPROVING PNEUMONIA VACCINATION RATES

35

project’s outcomes. Third, being that the project was constrained to one primary care location
findings may be limited in generalizability. However, comparative results to previous studies
with similar patient population’s leads the DNP student to speculate it was a fairly accurate
depiction of the population, thus strengthening the project’s external validity. Future research
should consider the effect of these limitations on the study’s findings and address them
accordingly.
Conclusion
Primary care providers uphold a pivotal role in preventive health maintenance, including
immunizations. This DNP project aimed to assess the feasibility of implementing a theorydriven, evidence-based educational intervention to increase rates of pneumococcal pneumonia in
adults 65 and older within the primary care setting. Results indicated that by increasing the
presence of educational material and introducing greater opportunities for patients to seek
information, the DNP student was able to increase cumulative rates of pneumococcal vaccination
(PCV-13 and PPSV-23) in the at risk population by nearly 10%. Furthermore, the project
elicited findings supportive of previous research, indicating that educational interventions aimed
at both patients and providers, are a plausible means of dismantling barriers and increasing
cumulative rates of vaccination in high-risk patient populations.
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Appendix A

Use of 13-Valent Pneumococcal Conjugate Vaccine and
23-Valent Pneumococcal Polysaccharide Vaccine Among Adults
Aged ≥65 Years: Recommendations of the Advisory Committee on
Immunization Practices (ACIP)
Sara Tomczyk, MSc1,2, Nancy M. Bennett, MD3,4, Charles Stoecker, PhD5, Ryan Gierke, MPH2, Matthew R. Moore, MD2,
Cynthia G. Whitney, MD2, Stephen Hadler, MD2, Tamara Pilishvili, MPH2 (Author affiliations at end of text)

On August 13, 2014, the Advisory Committee on Immunization
Practices (ACIP) recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth
Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.]) among adults
aged ≥65 years. PCV13 should be administered in series with
the 23-valent pneumococcal polysaccharide vaccine (PPSV23
[Pneumovax23, Merck & Co., Inc.]), the vaccine currently recommended for adults aged ≥65 years. PCV13 was approved by the
Food and Drug Administration (FDA) in late 2011 for use among
adults aged ≥50 years. In June 2014, the results of a randomized
placebo-controlled trial evaluating efficacy of PCV13 for preventing community-acquired pneumonia among approximately

Recommendations for routine use of vaccines in
children, adolescents, and adults are developed by
the Advisory Committee on Immunization Practices
(ACIP). ACIP is chartered as a federal advisory committee to provide expert external advice and guidance
to the Director of the Centers for Disease Control
and Prevention (CDC) on use of vaccines and related
agents for the control of vaccine-preventable diseases in
the civilian population of the United States. Recommendations for routine use of vaccines in children
and adolescents are harmonized to the greatest extent
possible with recommendations made by the American
Academy of Pediatrics (AAP), the American Academy
of Family Physicians (AAFP), and the American College of Obstetrics and Gynecology (ACOG). Recommendations for routine use of vaccines in adults are
harmonized with recommendations of AAFP, ACOG,
and the American College of Physicians (ACP).
ACIP recommendations adopted by the CDC Director become agency guidelines on the date published in
the Morbidity and Mortality Weekly Report
(MMWR). Additional information regarding ACIP
is available at http://www.cdc.gov/vaccines/acip.

85,000 adults aged ≥65 years with no prior pneumococcal vaccination history (CAPiTA trial) became available and were presented
to ACIP (1). The evidence supporting PCV13 vaccination of
adults was evaluated using the Grading of Recommendations,
Assessment,Development,andEvaluation(GRADE)framework
and determined to be type 2 (moderate level of evidence); the recommendation was categorized as a Category A recommendation
(2). This report outlines the new recommendations for PCV13
use, provides guidance for use of PCV13 and PPSV23 among
adults aged ≥65 years, and summarizes the evidence considered
by ACIP to make this recommendation.

Epidemiology of Pneumococcal Disease Among
Adults Aged ≥65 Years
Streptococcus pneumoniae (pneumococcus) remains a leading infectious cause of serious illness, including bacteremia,
meningitis, and pneumonia, among older adults in the United
States. Use of a 7-valent pneumococcal conjugate vaccine
(PCV7) since 2000 and PCV13 since 2010 among children
in the United States has reduced pneumococcal infections
directly and indirectly among children, and indirectly among
adults. By 2013, the incidence of invasive pneumococcal
disease (IPD) caused by serotypes unique to PCV13 among
adults aged ≥65 years had declined by approximately 50%
compared with 2010, when PCV13 replaced PCV7 in the
pediatric immunization schedule (3). However, in 2013 an
estimated 13,500 cases of IPD occurred among adults aged
≥65 years (3). Approximately, 20%–25% of IPD cases and
10% of community-acquired pneumonia cases in adults aged
≥65 years are caused by PCV13 serotypes and are potentially
preventable with the use of PCV13 in this population (3,4).

PCV13 Vaccine in Adults
On December 30, 2011, PCV13 was approved for use among
adults aged ≥50 years to prevent pneumonia and invasive disease
caused by S. pneumoniae serotypes contained in the vaccine. The
new use for Prevnar 13 was approved under FDA’s accelerated
approval pathway, which allows for earlier approval of products that provide meaningful therapeutic benefit over existing
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treatments for serious and life-threatening illnesses (5). FDA
defined “meaningful therapeutic benefit over existing treatments”
as protection of adults aged ≥50 years from nonbacteremic
pneumococcal pneumonia or nonbacteremic pneumococcal
pneumonia combined with protection from IPD (7). On June 20,
2012,ACIPrecommendedroutineuseofPCV13foradultsaged
≥19 years with immunocompromising conditions, functional or
anatomicasplenia,cerebrospinalfluidleak,or cochlearimplants
(6).The ACIPdecisionto recommendPCV13 use amongadults
aged≥65yearswasdeferreduntildatabecameavailableon1)the
impactofPCV13useinchildrenondiseaseinadults(i.e.,indirect
effects) and 2) the efficacyof PCV13 against noninvasive pneumococcalpneumoniaamongadults.In accordancewithaccelerated approval requirements, a randomized placebo-controlled
trial (CAPiTA trial) was conducted in the Netherlands among
approximately85,000 adults aged ≥65 years during 2008–2013
to verify and describe further the clinical benefit of PCV13 in
the prevention of pneumococcal pneumonia (1). The results of
theCAPiTAtrialdemonstrated45.6%(95%confidenceinterval
[CI] = 21.8%–62.5%) efficacy of PCV13 against vaccine-type
pneumococcalpneumonia,45.0%(CI=14.2%–65.3%)efficacy
against vaccine-type nonbacteremic pneumococcal pneumonia,
and 75.0% (CI = 41.4%–90.8%) efficacy against vaccine-type
IPD among adults aged ≥65 years (1).
Tworandomized, multicenter, immunogenicity studies conducted in the United States and Europe among older adults
showed that PCV13 induced an immune response as good
as or better than that induced by PPSV23 (7,8). Functional
antibody responses were measured 1 month after vaccination
using an opsonophagocyticactivity(OPA)assay.In adults aged
60–64 years with no prior pneumococcal vaccination, PCV13
elicited OPA geometric mean antibody titers (GMTs) to the
12 serotypescommontoboth vaccinesthat were comparable
with, or higher than, responses elicited by PPSV23 (7). In
adults aged ≥70 years who previously had been immunized with
asingledose of PPSV23 ≥5 years before enrollment, PCV13
elicited OPA responses that were comparable with those elicited
by PPSV23 for two serotypes andhigherfor 10 serotypes(8).
Immunogenicity studies evaluating responses to PCV7
and PPSV23 administered in series showed a better immune
response when PCV7 was administered first (9–12). An evaluation of immune response after a second pneumococcal vaccination administered 1 year after the initial study doses showed
thatsubjectswhoreceivedPPSV23astheinitialstudydosehad
lower OPA antibody responses after subsequent administration
of PCV13 than those who had received PCV13 as the initial
dosefollowedbyadoseof PPSV23, regardlessofthe level of
the initial OPA response to PPSV23 (9). Studies evaluating
the immune response after a sequence of PCV7 or PCV13
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What is currently recommended?
In 2010, the Advisory Committee on Immunization Practices
(ACIP) approved revised recommendations that all persons
should be vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23) at age 65 years. In 2012, ACIP made
recommendations for use of 13-valent pneumococcal conjugate
vaccine (PCV13) and PPSV23 for adults aged ≥19 years with
immunocompromising conditions.
Why are the recommendations being modified now?
PCV13 was approved by the Food and Drug Administration in
late 2011 for use among adults aged ≥50 years. In June 2014,
the results of a randomized placebo-controlled trial showing
efficacy of PCV13 against community-acquired pneumonia
among approximately 85,000 adults aged ≥65 years became
available and were presented to ACIP. The evidence supporting
PCV13 vaccination of adults was evaluated using the Grading of
Recommendations, Assessment, Development, and Evaluation
(GRADE) framework and determined to be type 2 (moderate
level of evidence); the recommendation was designated as a
Category A recommendation.
What are the new recommendations?
Both PCV13 and PPSV23 should be routinely administered in
series to all adults aged ≥65 years. The recommendations for
routine PCV13 use among adults aged ≥65 years will be reevaluated in 2018 and revised as needed. ACIP recommendations for
routine use of PCV13 in adults aged ≥19 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leak, or cochlear implants remain unchanged.

followed by PPSV23 with intervals of 2, 6, and 12 months or
3–4 yearsdemonstratedthatafterthe PPSV23dose,antibody
levels were higher than the pre-PCV baseline, and a noninferior response was observed when compared with post-PCV
antibody levels (9–12). None of the studies were designed to
evaluate the optimal interval between vaccine doses.
Safety of PCV13 was evaluated in approximately 6,000
PPSV23-naïve and PPSV23-experienced adults aged ≥50 years
(13). Overall incidence of serious adverse events reported within
1 month of an initial study dose of PCV13 or PPSV23 did
not differ between the two vaccines and ranged from 0.2% to
1.7%. From1 to 6 months after an initial study dose, the overall
incidence of serious adverse events ranged from 1.2% to 5.8%
among persons vaccinated with PCV13 and 2.4% to 5.5%
among persons vaccinated with PPSV23. Rates of reported serious adverse events in the treatment groups were similar among
studies that enrolled PPSV23-naïve subjects and studies that
enrolled PPSV23-experienced subjects. Common adverse reactions reported with PCV13 were pain, redness, and swelling at
the injection site; limitation of movement of the arm in which
the injection was given; fatigue; headache; chills; decreased appetite; generalized muscle pain; and joint pain. Similar reactions
wereobservedin adultswhoreceivedPPSV23(13).
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Indirect effects from PCV13 use among children, if similar to
those observed after PCV7 introduction, might further reduce
the remaining burden of adult pneumococcal disease causedby
PCV13-types. A preliminary analysis using a probabilistic model
following a single cohort of persons aged 65 years demonstrated
thataddinga dose of PCV13 to the currentPPSV23 recommendations for adults aged ≥65 years, compared with current PPSV23
recommendations, would lead to additional health benefits (14).
This strategy would prevent an estimated 230 cases of IPD and
approximately 12,000 cases of community-acquired pneumonia
overthelifetimeofa singlecohortof personsaged65years,assuming current indirect effects from the child immunization program
and currentPPSV23vaccinationcoverageamongadultsaged ≥65
years (approximately 60%). In a setting of fully realized indirect
effects assuming the same vaccination coverage, the expected
benefits of PCV13 use among this cohort will likely decline to
an estimated 160 cases of IPD and 4,500 cases of communityacquired pneumonia averted among persons aged ≥65 years (14).
CDC will assess the implementation and impact of the recommendation for PCV13 use among adults aged≥65 years, including
coverage with PCV13 and PPSV23, and impact of PCV13 on
vaccine-type IPD burden and community-acquired pneumonia.
Monitoringdiseasetrendsamongadultswhodo notreceivePCV13
might help quantify indirect effects and the long-term utility of
routine PCV13 use among adults. ACIP will be updated routinely
on changes in the burden of IPD and community-acquired pneumonia among adults during the next 3 years to determine the need
for revisions to the adult PCV13 recommendations.

PPSV23 inAdults
A single dose of PPSV23 is recommended for routine use in
the United States among adults aged ≥65 years (15). Effectiveness
of PPSV23 in preventing IPD in adults has been demonstrated,
but the data on the effectiveness of this vaccine in preventing
noninvasive pneumococcal pneumonia among adults aged≥65
years have been inconsistent. PPSV23 contains 12 serotypes in
common with PCV13 and 11 additional serotypes. In 2013, 38%
of IPD among adults aged ≥65 years was caused by serotypes
unique to PPSV23 (3). Given the high proportion of IPD caused
by serotypes unique to PPSV23, broader protection is expected to
be provided through use of both PCV13 and PPSV23 in series.
ACIP considered multiple factors when determining the optimal interval between a dose of PCV13 and PPSV23, including
immune response, safety, the risk window for protection against
disease caused by serotypes unique to PPSV23, as well as timing
for the next visit to the vaccination provider.

ACIP Recommendations for PCV13 and PPSV23 Use
Both PCV13 and PPSV23 should be administered routinely
in series to all adults aged ≥65 years (Box).
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Pneumococcal vaccine-naïve persons. Adults aged ≥65 years
who have not previously received pneumococcal vaccine or
whose previous vaccination history is unknown should receive
a dose of PCV13 first, followed by a dose of PPSV23. The
dose of PPSV23 should be given 6–12 months after a dose of
PCV13. If PPSV23 cannot be given during this time window,
the dose of PPSV23 should be given during the next visit. The
two vaccines should not be coadministered, and the minimum
acceptable interval between PCV13 and PPSV23 is 8 weeks.
Previous vaccination with PPSV23. Adults aged ≥65 years who
have previously received ≥1 doses of PPSV23 also should receive a
dose of PCV13 if they have not yet received it. A dose of PCV13
should be given ≥1 year after receipt of the most recent PPSV23 dose.
For those for whom an additional dose of PPSV23 is indicated, this
subsequent PPSV23 dose should be given 6–12 months after PCV13
and ≥5 years after the most recent dose of PPSV23 (15).
Potential Time-Limited Utility of Routine PCV13 Use
Among Adults ≥65 Years.The recommendations for routine
PCV13 use among adults aged ≥65 years will be reevaluated
in 2018 and revised as needed.
ACIP recommendations for routine use of PCV13 in adults
aged ≥19 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leak, or cochlear
implants remain unchanged (6).

Coadministration with Other Vaccines
Concomitant administration of PCV13 and trivalent inactivated influenza vaccine (TIV) has been demonstrated to be immunogenic and safe. PCV13 can be coadministered with TIV in an
adult immunization program. However, a randomized doubleblind trial found slightly lower pneumococcal serotype–specific
geometric mean concentrations and lower proportion achieving
at least a fourfold rise in hemagglutination inhibition assay titer
for one of three influenza subtypes (influenza A[H3N2]) with
PCV13 plus TIV compared with PCV13 alone or TIV alone
among adults aged ≥65 years (16). Currently, no data are available
on coadministration with other vaccines (e.g., tetanus, diphtheria,
and acellular pertussis vaccine or zoster vaccine) among adults.

Precautions and Contraindications
Before administering PCV13, vaccination providers should
consult the package insert for precautions, warnings, and
contraindications. Vaccination with PCV13 is contraindicated
in persons known to have a severe allergic reaction (e.g., anaphylaxis) to any component of PCV13 or PCV7 or to any
diphtheria toxoid–containing vaccine.
Adverse events occurring after administration of any vaccine
should bereportedtotheVaccineAdverseEventReportingSystem
(VAERS). Reports can be submitted to VAERS online, by fax,
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BOX. Sequential administration and recommended intervals for
PCV13 and PPSV23 for adultsaged ≥65 years — Advisory Committee
on Immunization Practices, United States

6–12 months*

PCV13

who are now aged ≥65 years
PPSV23 already received

PPSV23

6–12 months*

or by mail. Additional information about VAERS is available by
telephone (1-800-822-7967) or online (http://vaers.hhs.gov).
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Announcement
Now Available Online: Final 2013–14 Influenza Vaccination Coverage Estimates for Selected Local Areas,
States, and the United States
Final 2013–14 influenza season vaccination coverage esti- mates are now available online at FluVaxView (http://www.cdc.
gov/flu/fluvaxview).The online information includes estimates of the cumulative percentage of persons vaccinated by the end of
each month, from July 2013 through May 2014, for select local areas, each state, each U.S. Department of Health and Human
Services region, and the United States overall.
Analyses were conducted using National Immunization Survey influenza vaccination data for children aged 6 months–17 years and
Behavioral Risk Factor Surveillance System data for adults aged ≥18 years. Estimates are provided by age group and race/ ethnicity.
These estimates are presented in an interactive report (http://www.cdc.gov/flu/fluvaxview/interactive.htm) and complemented
by an online summary report (http://www.cdc. gov/flu/fluvaxview/coverage-1314estimates.htm).

QuickStats
FROMTHENATIONAL CENTERFORHEALTHSTATISTICS

Age-Adjusted Death Rates* for Heart Disease and Cancer,† by Sex
— United States, 1980–2011
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† As the underlying cause of death, heart disease is coded as 390–398, 402, and 404–429 for the
period 1980–1998, and I00–I09, I11, I13, and I20–I51 for 1999–2011. As the underlying cause of death,
cancer is coded as 140–208 for the period 1980–1998 and C00–C97 for 1999–2011, based on the
International Classification of Diseases, Ninth and Tenth Revisions.

During 1980–2011, age-adjusted death rates for heart disease in males and females decreased steadily. The rate
decreased 59.5% for males and 56.8% for females. In contrast, the rate from cancer first increased 3.4% for males and
5.3% for females during 1980–1990 and then decreased 27.2% for males and 18.0% for females by 2011. For females, the
rates for cancer (147.4 per 100,000 population) surpassed the rates for heart disease (146.6) in 2009. The death rate for heart
disease in males remained slightly higher (218.1) than the death rate for cancer (204.0) in 2011.
Source: National Vital Statistics System. Mortality public use data files, 1980–2011. Available at http://www.cdc.gov/nchs/data_access/
vitalstatsonline.htm.
Reported by: Jiaquan Xu, MD, jax4@cdc.gov, 301-458-4086.
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Appendix B
Standing Orders for Administering Pneumococcal (PPSV23 and PCV13) Vaccine to Adults
Purpose: To reduce morbidity and mortality from pneumococcal disease by vaccinating all adults who meet the criteria established
by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices.
Policy: Under these standing orders, eligible nurses and other healthcare professionals (e.g., pharmacists), where allowed by state law,
may vaccinate adults who meet any of the criteria below.

Procedure
1. Identify adults in need of vaccination with pneumococcal conjugate vaccine (PCV13) based on the following criteria:
a. Age 65 years or older with no or unknown history of prior receipt of PCV13
b. Age 19 through 64 years with no or unknown history of prior receipt of PCV13 and any of the following conditions:
i. candidate for or recipient of cochlear implant; cerebrospinal fluid leak
ii. functional or anatomic asplenia (e.g., sickle cell disease, splenectomy)
iii. immunocompromising condition (e.g., HIV infection, congenital immunodeficiency, hematologic and solid tumors)
iv. immunosuppressive therapy (e.g., alkylating agents, antimetabolites, long-term systemic corticosteroids, radiation
therapy)
v. organ or bone marrow transplantation; chronic renal failure or nephrotic syndrome
2. Identify adults in need of vaccination with pneumococcal polysaccharide vaccine (PPSV23) based on the following criteria:
a. Age 65 years or older with no or unknown history of prior receipt of PPSV23
b. Age 19 through 64 years with no or unknown history of prior receipt of PPSV23 and any of the following conditions:
i. chronic cardiovascular disease (e.g., congestive heart failure, cardiomyopathies)
ii. chronic pulmonary disease (e.g., chronic obstructive pulmonary disease, emphysema, asthma)
iii. diabetes mellitus, alcoholism or chronic liver disease (cirrhosis), cigarette smoker
iv. any of the conditions specified in categories 1.b. above
3. Identify adults in need of an additional dose of PPSV23 if 5 or more years have elapsed since the previous dose of PPSV23
and the patient meets one of the following criteria:
a. Age 65 years or older and received prior PPSV vaccination before age 65 years
b. Age 19 through 64 years and at highest risk for serious pneumococcal infection or likely to have a rapid decline in
pneumococcal antibody levels (i.e., categories 1.b.ii.–1.b.v. above)
4. Screen all patients for contraindications and precautions to pneumococcal vaccine:
a. Contraindication: a history of a serious reaction (e.g., anaphylaxis) after a previous dose of pneumococcal vaccine (PPSV or
PCV13) or to a vaccine component. For a information on vaccine components, refer to the manufacturer’s package insert
(www.immunize.org/package- inserts) or go to www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipienttable-2.pdf.
b. Precaution: moderate or severe acute illness with or without fever
5. Provide all patients with a copy of the most current federal Vaccine Information Statement (VIS). While only the VIS for PCV13
is required by federal law, it is prudent to also provide the VIS for PPSV23 to patients receiving PPSV23. For both vaccines,
document in the patient’s medi- cal record or office log, the publication date of the VIS and the date it was given to the patient.
Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be
found at www.immunize.org/vis.
6. Administer vaccine as follows:
a. For adults identified in 1. above, administer 0.5 mL PCV13 intramuscularly (22–25g, 1–1½" needle) in the deltoid muscle.
b. For adults identified in 2. and 3. above, administer 0.5 mL PPSV23 vaccine either intramuscularly (22–25g, 1–1½" needle)
in the deltoid muscle or subcutaneously
(23–25g, 5/ " needle) in the posterolateral fat of the upper arm.
8
c. For adults in need of both PCV13 and PPSV23, administer PCV13 first, followed by PPSV23 in 6–12 months. (Note: for
adults with im- munocompromising conditions or functional or anatomic asplenia, give PPSV23 8 weeks following
PCV13.) If previously vaccinated with PPSV23, give PCV13 at least 12 months following PPSV23. Do not give PCV13
and PPSV23 at the same visit.
(Note: A 5/8" needle may be used for IM injection for patients who weigh less than 130 lbs [60kg] for injection in the deltoid
muscle, only if the subcutaneous tissue is not bunched and the injection is made at a 90-degree angle.)
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7. Document each patient’s vaccine administration information and follow up in the following places:
a. Medical chart: Record the date the vaccine was administered, the manufacturer and lot number, the

vaccination site and route, and the name and title of the person administering the vaccine. If vaccine was not
given, record the reason(s) for non-receipt of the vaccine (e.g., medical contraindication, patient refusal).
b. Personal immunization record card: Record the date of vaccination and the name/location of the administering
clinic.
8. Be prepared for management of a medical emergency related to the administration of vaccine by having a written
emergency medical proto- col available, as well as equipment and medications.
9. Report all adverse reactions to PPSV23 and PCV13 to the federal Vaccine Adverse Event Reporting System
(VAERS) at www.vaers.hhs.gov or by calling (800) 822-7967. VAERS report forms are available at
www.vaers.hhs.gov.
This policy and procedure shall remain in effect for all patients of the
rescinded or until
Medical Director’s signature:

(date).

For standing orders for other vaccines, go to www.immunize.org/standingorders

until
(name of practice orclinic)

Effective date:

Technical content reviewed by the Centers for

Disease Control and
Prevention
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Appendix C
Community Health Improve Process (CHIP)

Adapted from “Improving Health in the Community: A Role for Performance Monitoring,” by J.S.
Durch, L.A. Bailey, and M.A. Stoto, 1997, International Journal of Health Planning and
Management,13(2), p. 191-192. Copyright 1997 by the National Academy Press.
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Appendix E
Flow Chart of Program Processes

Educate Key Stakeholders








Provide project manager and site chief with cost/benefit analyses
Conduct educational/training session with staff/providers
PowerPoint presentation on pneumococcal pneumonia, benefits to vaccination and the benefits
to the proposed project
Increase providers awareness of ACIP recommended standing orders for PPSV-23/PCV-13
vaccines; offer copy
Post-educational session surveys, including open-ended questions, to assess opinions and
willingness to participate
Address potential barriers and methods to eliminate them
Remain available to address questions/concerns of staff/providers

Promote Project Awareness Among Patients




Provide patients with Vaccine Information Sheets
Hang and distribute flyers with pertinent information regarding pneumococcal pneumonia and
the importance of vaccination
Encourage providers and staff to educate patients on pneumococcal pneumonia and
vaccination during any available and appropriate opportunity

Implement/Evaluate Intervention


Gather and analyze pre/post-intervention de-identified data on pneumococcal vaccination rates
among target population

Assess program effectiveness and future
applicability; share findings with key
stakeholders and student’s capstone
committee
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Appendix F

Pneumococcal Disease:
Are You and Your Loved Ones Protected ?
What Is Pneumococcal Disease?
Why Vaccinate?

Pneumococcal disease is one of

death every year in the U.S.

the leading causes of death

(American Lung Association

throughout the world. It is an

[ALA], 2010). Nearly one

easily transmitted,

million people willdevelop

significantly infectiousillness

pneumococcal pneumoniain

cause by a commonbacteria

the U.S. in the next year and 5

Many studies have demonstrated

pneumococcus, and resultsin

to 7 perfect of them will die;

pneumococcal vaccination to

massive expense,

the death rate is even higher

effective protect against invasive

complications (i.e. pneumonia,

in adults 65 years of age and

and noninvasive pneumococcal

meningitis or sepsis) and

older.

disease.

•••
Getting vaccinated is the most
effective and safest way to protect
yourself and your loved ones.

Vaccines aid in protecting your

Pneumococcal disease claims the lives of one in
every four to five people over the age of 65 that
contracts it.

body against various strains of
bacteria.
There are two currently
recommended vaccines for older
adults:

Did You Know?
Adults 65 and older are at a higher

risk.

As humans age our immune

the CDC (2011), 80% of older

defenses become weaker,

adults are diagnosed with a

making us more susceptible to

chronic illness and 50% with

illnesses such as pneumonia.

two or more.

Patients suffering from
chronic diseases are further
limited in their ability to fight

Some strains of pneumococcal
are resistant to antibiotics,

FAST FACT:

infection and suffer a greater

Patients 65 and older have

risk for potential

the highest expenditures of

complications. According to

• Pneumococcal Polysaccharide
(PPSV23)
• Pneumococcal Conjugate
(PCV13)

pneumonia among all age
groups in the U.S.

making infections difficult to
treat.
Prevention through
vaccination
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Appendix G

Screening Checklist for Contraindications to
Vaccines for Adults
For patients: The following questions will help us determine which vaccines you may be given today. If you
answer “yes” to any question, it does not necessarily mean you should not be vaccinated. It just means
additional questions must be asked. If a question is not clear, please ask your healthcare provider to explain
it.
Yes

Don’t
Know

No

1. Are you sick today?







2. Do you have allergies to medications, food, a vaccine component, or latex?







3. Have you ever had a serious reaction after receiving a vaccination?







4. Do you have a long-term health problem with heart disease, lung disease, asthma,
kidney disease, metabolic disease (e.g., diabetes), anemia, or other blood disorder?





5. Do you have cancer, leukemia, HIV/AIDS, or any other immune system problem?







6. In the past 3 months, have you taken medications that weaken your immune system,
such as cortisone, prednisone, other steroids, or anticancer drugs, or have you had
radiation treatments?







7. Have you had a seizure or a brain or other nervous systemproblem?







8. During the past year, have you received a transfusion of blood or blood products,
or been given immune (gamma) globulin or an antiviral drug?







9. For women: Are you pregnant or is there a chance you could become pregnant
during the next month?







10. Have you received any vaccinations in the past 4 weeks?





Form completed by:

Date:

Form reviewed by:

Date:

Did you bring your immunization record card with you?

yes no 





It is important for you to have a personal record of your vaccinations. If you don’t have a personal record, ask
your healthcare provider to give you one. Keep this record in a safe place and bring it with you every time you
seek medical care. Make sure your healthcare provider records all your vaccinations on it.
Technical content reviewed by the Centers for Disease Control and Prevention

Immunization Action Coalition Saint Paul, Minnesota • 651 - 647 - 9009 • www.immunize.org • www.vaccineinformation.org
www.immunize.org/catg.d/p4065.pdf • Item #P4065 (1/15)

IMPROVING PNEUMONIA VACCINATION RATES

54

Information for Health Professionals about the Screening Checklist for Contraindications To Vaccines for Adults
Are you interested in knowing why we included a certain question on the screening checklist? If so, read the information
below. If you want to find out even more, consult the references listed at the bottom of this page.
1. Are you sick today? [all vaccines]
There is no evidence that acute illness reduces vaccine efficacy or increases
vaccine adverse events (1). However, as a precaution with moderate or severe acute illness, all vaccines should be delayed until the illness has improved.
Mild illnesses (such as upper respiratory infections or diarrhea) are NOT
contraindicationstovaccination.Donotwithholdvaccinationifapersonistaking
antibiotics.

2. Do you have allergies to medications, food, a vaccine component,
or latex? [all vaccines]
If a person has anaphylaxis after eating gelatin, do not administer MMR or
varicella vaccine. A local reaction to a prior vaccine dose or vaccine components (e.g., latex) is not a contraindication to a subsequent dose or vaccine
containing that component. For a table of vaccines supplied in vials or syringes
that contain latex, go towww.cdc.gov/vaccines/pubs/pinkbook/downloads/
appendices/B/latex-table.pdf. For an extensive list of vaccine components, see
reference 2.
An egg-free recombinant influenza vaccine (RIV3) may be used in people
age 18 years and older with egg allergy of any severity who have no other
contraindications. People younger than age 18 years who have experienced
a serious systemic or anaphylactic reaction (e.g., hives, swelling of the lips or
tongue, acute respiratory distress, or collapse) after eating eggs can usually be
vaccinated with inactivated influenza vaccine (IIV); consult ACIP recommendations (seereference3).
3. Have you ever had a serious reaction after receiving a
vaccination? [all vaccines]
History of anaphylactic reaction (see question 2) toa previous dose of vaccine
or vaccine component is acontraindication for subsequent doses (1). Under
normal circumstances, vaccines are deferred when a precaution is present.
However, situations may arise when the benefit outweighs the risk (e.g., during
acommunitypertussis outbreak).

4. Do you have a long-term health problem with heart disease,
lung disease, asthma, kidney disease, metabolic disease (e.g.,
diabetes), anemia, or other blood disorder? [LAIV]
The safety of intranasal live attenuated influenza vaccine (LAIV) in people with
these conditions has not been established. These conditions, including asthma
in adults, should be considered precautions for the use of LAIV.

5. Do you have cancer, leukemia, HIV/AIDS, or any other immune system problem? [LAIV, MMR, VAR, ZOS]
Live virus vaccines (e.g., LAIV, measles-mumps-rubella [MMR], varicella [VAR],
zoster [ZOS]) are usually contraindicated in immunocompromised people.
However, there are exceptions. For example, MMR vaccine is recommended
and varicella vaccine should be considered for adults with CD4+ T-lymphocyte counts of greaterthan or equalto 200 cells/µL. Immunosuppressed people
should not receive LAIV. For details, consult the ACIP recommendations (1, 4, 5).

6. In the past 3 months, have you taken medications that
weaken your immune system, such as cortisone, prednisone,
other steroids, or anticancer drugs, or have you had radiation
treatments? [LAIV, MMR, VAR, ZOS]
Live virus vaccines (e.g., LAIV, MMR, VAR, ZOS) should be postponed until
after chemotherapy or long-term high-dose steroid therapy has ended. For
details and length of time to postpone, consult the ACIP statement (1, 3). To
find specific vaccination schedules for stem cell transplant (bone marrow transplant) patients, see reference 6. LAIV can be given only to healthy non-pregnant
people younger than age 50 years.

7. Have you had a seizure or a brain or other nervous system
problem? [influenza, Td/Tdap]
Tdapis contraindicatedin peoplewhohaveahistoryof encephalopathywithin
7 days following DTP/DTaP given before age 7 years. An unstable progressive
neurologic problem is a precaution to the use of Tdap. For people with stable
neurologic disorders (including seizures) unrelated to vaccination, or for people
with a family history of seizure, vaccinate as usual. A history of Guillain-Barré
syndrome (GBS) is a consideration with the following: 1) Td/Tdap: if GBS has
occurredwithin 6 weeks of atetanus-containing vaccine and decision is made
to continue vaccination, give Tdap instead of Td if no history of prior Tdap; 2)
Influenza vaccine (IIV/LAIV): if GBS has occurred within 6 weeks of a prior influenza vaccine, vaccinate with IIV if at high risk for severe influenza complications.

8. During the past year, have you received a transfusion of blood
or blood products, or been given immune (gamma) globulin or an
antiviral drug? [LAIV, MMR, VAR]
Certain live virus vaccines (e.g., LAIV, MMR, VAR, ZOS) may need to be
deferred, depending on several variables. Consult the most current ACIP
recommendations for current information on intervals between antiviral drugs,
immune globulin or blood product administration and live virus vaccines. (1)

9. For women: Are you pregnant or is there a chance you could
become pregnant during the next month? [MMR, LAIV, VAR, ZOS]
Live virus vaccines (e.g., MMR, VAR, ZOS, LAIV) are contraindicated one
month before and during pregnancy because of the theoretical risk of virus
transmissiontothe fetus. Sexually active women in their childbearing years
who receive live virus vaccines should be instructed topractice careful contraception for one month following receipt of the vaccine. On theoretical
grounds, inactivated poliovirus vaccine should not be given during pregnancy;
however, it may be given if risk of exposure is imminent and immediate protection is needed (e.g., travel to endemic areas). Use of Td or Tdap is not
contraindicated in pregnancy. At the provider’s discretion, either vaccine may
be administered during the 2nd or 3rd trimester. (1, 3, 4, 5, 7, 8)

10. Have you received any vaccinations in the past 4 weeks?
[LAIV, MMR, VAR, yellow fever] People who were given either LAIV or an injectable live virus vaccine (e.g., MMR, VAR, ZOS, yellow fever) should wait 28
days before receiving another vaccination of this type. Inactivated vaccines may
be given at any spacing interval if they are not administered simultaneously.
References:
1. CDC. General recommendations on immunization, at www.cdc.gov/vaccines/
pubs/acip-list.htm
2. Table of Vaccine Components: www.cdc.gov/vaccines/pubs/pinkbook/downloads/
appendices/B/excipient-table-2.pdf.
3. CDC. Prevention and control of seasonal influenza with vaccines: Recommendations of the ACIP—2014–2015 Influenza Season at www.cdc.gov/mmwr/pdf/wk/
mm6332.pdf, pages 691–7.
4. CDC. Measles, mumps, and rubella—vaccine use and strategies for elimination
of measles, rubella, and congenital rubella syndrome and control of mumps.
MMWR 1998; 47 (RR-8).
5. CDC. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices. MMWR 2007; 56 (RR-4).
6. Tomblyn M, Einsele H, et al. Guidelines for preventing infectious complications
among hematopoietic stemcell transplant recipients: a global perspective. Biol Blood
MarrowTransplant 15:1143–1238; 2009at www.cdc.gov/vaccines/pubs/hematocell-transplts.htm.
7. CDC. Notice to readers: Revised ACIP recommendation for avoiding pregnancy
after receiving a rubella-containing vaccine. MMWR 2001; 50 (49).
8. CDC. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartumwomenandtheirinfants:RecommendationsoftheACIP.MMWR2008;57(RR-4).
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Appendix H

Educational Component #1: Post-session
Questionnaire
Thank you for taking a few moments of your time to complete the brief questionnaire
below. Your honest feedback is encouraged and extremely valuable; it ensures
successful implementation of a project that will address your needs, while also
providing long-term benefits to both the office and its valued patients.

,

Please rate the following statements on the extent to which you agree or disagree:
Strongly
Disagree

Disagree Neutral

Agree

The material presented during this session was
educational and applicable to my job.
The information increased my awareness of how
significant the problem of suboptimal pneumococcal
vaccination rates is.
The student clearly identified the problem and
proposed intervention for addressing the problem.
I think a Standing Orders Program will help to
increase rates of pneumococcal vaccination amongst
our patients 65 and older.
I am confident that staff will be able to successfully
implement a Standing Orders Program.
Patients will be receptive to this project.

1.) What, if any, are your concerns regarding the proposedintervention?

2.) Do you feel that a Standing Orders Program will work effectively at your
site? Why or why not?

3.) Please provide any feedback that you believe will be beneficial in making
this project a success for the staff, patients and student:

Strongly
Agree
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Appendix I
Goals and Objectives of Proposed Capstone Intervention
Goal I. Identify a multidisciplinary team within primary care to design and implement a program that
meets both state and federal regulatory requirements and national vaccination goals.
Objective
i. Increase staff and provider awareness of
the significance of the problem (i.e.
suboptimal pneumococcal vaccination
rates among adults 65 and older) and
justify the need for the chosen
intervention.

ii. Increase provider and staff awareness
of potential barriers to achieving targeted
vaccination rates

iii. Increase provider and staff awareness
of recommendations and regulations
regarding SOPs for vaccines

iv. Increase pertinent stakeholder’s
knowledge of project’s key components,
including the following secondary
objectives:
iv-1.1 Immunization practices
iv-1.2HealthyPeople 2020 objectives
iv-1.3 CDC eligibility criteria for

Outcome Measures
a. An educational session/practice meeting will be
conducted within the first 1-2 weeks of the semester
(middle to end of September).
b. A post-educational session questionnaire will be
distributed to staff to determine if the presentation
was successful in achieving this objective. At least
80% of participants will provide feedback.
a. A practice meeting will be conducted within the
first week of student beginning final capstone
rotation; at the close of the meeting 90% of
participants will be educated on HCP, system and
patient barriers previously identified by the student
in current evidence-based research.
b. A survey will be conducted at the end of the
meeting – at least 60% of providers and staff will
agree that a SOP can help alleviate at least one
barrier.
a. 90% of the practice’s providers (MDs and NPs)
and clinical staff will be provided a copy of the
Immunization Action Coalition’s standing orders
for administration of PPSV23 and PCV13 to adults.
b. 90% of providers and staff will provided a copy
of the Massachusetts Department of Public Health –
Model Standing Orders for both PPSV23 and
PCV13.
c. 90% of providers will be informed of the
recommendations by Advisory Committee on
Immunization Practices (ACIP) and Centers for
Medicare and Medicaid on the use of SOPs.
a. 80% of key stakeholders will attend two separate
educational sessions between 9/9 and 11/1 that will
address all components of objective.
b. At the end of the in-service a post-session
questionnaire will be distributed; at least 80% of
attendees will complete it.
a. An SOP will be implemented by November 2nd,
2015.
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PPSV23 and PCV13 vaccines
iv-1.4 Core concepts of disease risk
criteria for target population
iv-1.5 Utilization and analysis of
patient data in EHR
iv-1.6 Vaccine order procedures.
iv. Establish, implement and evaluate a
standing orders program that will be
utilized and accessible by appropriate key
stakeholders.

b. By Spring 2016, at least 60% of providers and
staff will express willingness to utilize SOPs in the
future.

Goal II. Ensure all eligible adults age 65 and older in primary care are effectively motivated
and informed of current pneumococcal vaccination recommendations and provided an opportunity
for vaccination.
Objective
i. Establish baseline data for
vaccination rates of patients aged
65 and older in the practice
ii. Identify and eliminate missed
vaccination opportunities

iii. Increase patient awareness of
pneumococcal disease and vaccine
availability.

Outcome Measures
a. Baseline data will be gathered and reviewed prior to the
2015-2016 influenza season
a. By 10/15/15, 75% of providers will assess their
schedule for a previous work week and identify at least 3
patients that were due for a pneumococcal vaccine but it
wasn’t discussed
b. Providers will report discussing pneumococcal
vaccination with at least 75% of eligible patients by the
end of the 2015-2016 influenza season
c. 60% of providers will report assessing and discussing
vaccination status at every clinical encounter
a. 90% of adult patients 65 and older or their patient
representatives will be provided a flyer and screening tool
on pneumococcal disease and vaccination upon check-in.
b. Flyers will be hung in all exam rooms by the end of
September 2015
c. An educational poster regarding pneumococcal disease
and vaccination will be hung in the waiting room by the
end of September 2015
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Goals Related to Population
Goal III. Reduce overall morbidity and mortality caused by pneumococcal disease among
adults age 65 and older in primary care.

Objective
i. Expand immunization services

Outcome Measures
a. At least 75% of patients age 65 and older will complete
screening and be administered a pneumococcal vaccine if
determined to be eligible.

ii. Increase the annual
immunization rates of adults age 65
and older who are vaccinated
against pneumonia in primary care.

a. In line with HealthyPeople 2020, a target 90% of the
practice’s patients aged 65 and older will have received a
pneumococcal vaccination by the end of the 2015-2016
influenza season.
b. Improve practice’s pneumococcal vaccine coverage by
at least 20% before the end of the 2015-2016 influenza
season

